Hervas-Stubbs Sandra, Majlessi Laleh, Simsova Marcela, Morova Jana, Rojas Marie-Jesus, Nouzé Clémence, Brodin Priscille, Sebo Peter, Leclerc Claude
Biologie des Régulations Immunitaires, Inserm, E 352, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France.
Infect Immun. 2006 Jun;74(6):3396-407. doi: 10.1128/IAI.02086-05.
TB10.4 is a newly identified antigen of Mycobacterium tuberculosis recognized by human and murine T cells upon mycobacterial infection. Here, we show that immunization with Mycobacterium bovis BCG induces a strong, genetically controlled, Th1 immune response against TB10.4 in mice. BALB/c and C57BL/6 strains behave as high and low responders to TB10.4 protein, respectively. The TB10.4:74-88 peptide was identified as an immunodominant CD4+ T-cell epitope for H-2d mice. Since recent results, as well as the present study, have raised interest in TB10.4 as a subunit vaccine, we analyzed immune responses induced by this antigen delivered by a new vector, the adenylate cyclase (CyaA) of Bordetella pertussis. CyaA is able to target dendritic cells and to deliver CD4+ or CD8+ T-cell epitopes to the major histocompatibility complex class II/I molecule presentation pathways, triggering specific Th1 or cytotoxic T-lymphocyte (CTL) responses. Several CyaA harboring either the entire TB10.4 protein or various subfragments containing the TB10.4:20-28 CTL epitope were shown to induce TB10.4-specific Th1 CD4+ and CD8+ T-cell responses. However, none of the recombinant CyaA, injected in the absence of adjuvant, was able to induce protection against M. tuberculosis infection. In contrast, TB10.4 protein administered with a cocktail of strong adjuvants that triggered a strong Th1 CD4+ T-cell response induced significant protection against M. tuberculosis challenge. These results confirm the potential value of the TB10.4 protein as a candidate vaccine and show that the presence of high frequencies of CD4+ T cells specific to this strong immunogen correlates with protection against M. tuberculosis infection.
TB10.4是结核分枝杆菌新发现的一种抗原,在分枝杆菌感染后可被人和小鼠的T细胞识别。在此,我们表明用牛分枝杆菌卡介苗免疫可在小鼠中诱导针对TB10.4的强烈的、受基因控制的Th1免疫反应。BALB/c和C57BL/6品系分别对TB10.4蛋白表现为高反应者和低反应者。TB10.4:74 - 88肽被确定为H - 2d小鼠的免疫显性CD4 + T细胞表位。由于近期的研究结果以及本研究都引发了对TB10.4作为亚单位疫苗的兴趣,我们分析了由新载体百日咳博德特氏菌的腺苷酸环化酶(CyaA)递送的该抗原所诱导的免疫反应。CyaA能够靶向树突状细胞,并将CD4 +或CD8 + T细胞表位递送至主要组织相容性复合体II / I类分子呈递途径,触发特异性Th1或细胞毒性T淋巴细胞(CTL)反应。几种携带完整TB10.4蛋白或包含TB10.4:20 - 28 CTL表位的各种亚片段的CyaA被证明可诱导TB10.4特异性的Th1 CD4 +和CD8 + T细胞反应。然而,在无佐剂情况下注射的重组CyaA均不能诱导对结核分枝杆菌感染的保护作用。相反,与引发强烈Thl CD4 + T细胞反应的强效佐剂混合物一起给予的TB10.4蛋白可诱导对结核分枝杆菌攻击的显著保护作用。这些结果证实了TB10.4蛋白作为候选疫苗的潜在价值,并表明针对这种强免疫原的高频CD4 + T细胞的存在与对结核分枝杆菌感染的保护作用相关。